ID   HyCyte Daudi KO-hCD72
AC   CVCL_E1JS
SY   hCD72 knockout Daudi
DR   Hysigen; CGKO-M2701
CC   Population: African; Kenyan.
CC   Doubling time: 24-48 hours (Hysigen=CGKO-M2701).
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; HGNC:1696; CD72.
CC   Sequence variation: Gene fusion; HGNC; HGNC:5477; IGH + HGNC; HGNC:7553; MYC; Name(s)=MYC-IGH (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:914; B2M; Simple; p.Met1Ile (c.3G>C); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:2514; CTNNB1; Simple; p.Ala5_Ala80del (c.14_241del228); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0008 ! Daudi
SX   Male
AG   16Y
CA   Cancer cell line
DT   Created: 10-09-24; Last updated: 19-12-24; Version: 2
//